GSK Signed a Multiyear Exclusive Collaborative Agreement with 23andMe to use Genetic Databases to Develop Novel Therapies.
- With this collaboration GSK plans improve target selection to develop “Precision Medicine” with better efficacy and safety
- To identify specific subgroups population to develop targeted treatments
- GSK is initially planning to leverage 23andMe databases for the development of its LRRK2i molecule in preclinical stage targeting Parkinson’s
Click here to read full press release/ article | Ref: GSK | Image: widdowquinn/Flickr